Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-12-27

FDA Approved: STRIVERDI RESPIMAT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approves a supplemental application for STRIVERDI RESPIMAT (olodaterol inhalation spray) from Boehringer Ingelheim Pharmaceuticals, expanding/ updating …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Striverdi Respimat (olodaterol)

Snippet

SUPPL AP for STRIVERDI RESPIMAT (OLODATEROL RESPIMAT INHALATION SPRAY)